Robert M. Califf, M.D.
February 15, 2022 — The leaders of three of the nation’s leading cardiology groups – American Heart Association President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA; American College of Cardiology President Dipti Itchhaporia, MD, FACC and Association of Black Cardiologists Michelle A. Albert, MD, MPH – issued the following statement expressing support for the nomination of Robert M. Califf, M.D. as commissioner of the Food and Drug Administration (FDA) and urging a timely Senate confirmation vote:
“Dr. Califf is an accomplished cardiologist, researcher and clinical trials expert who has been a driving force in the fight against heart disease and stroke throughout his career. His extensive experience, combined with his previous leadership of the FDA, will be invaluable as the agency continues to tackle a formidable set of public health challenges.
“As the FDA works to ensure the safety and effectiveness of COVID-19 vaccines, reduce the harm caused by tobacco products, secure food safety, promote good nutrition and streamline the process of drug and device development and review, it requires a permanent leader to oversee these and other critical public health priorities. Dr. Califf is uniquely suited to fill the role of FDA commissioner and manage the agency’s vital efforts to promote public health and reduce the burden of chronic disease.
“We know from experience that Dr. Califf will prioritize science and evidence-based policymaking at the helm of the FDA, just as he has throughout his impressive career. On behalf of the thousands of cardiologists and the millions of cardiovascular disease patients nationwide, we urgently ask the Senate to confirm Dr. Califf with bipartisan support.”
April 11, 2024 
